Management of hyperlipidemia

Alternative Therapies in Health and Medicine

Volumn 9, Issue 3, 2003, Pages 28-40

  Dog, Tieraona Low ^a   Riley, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLICIN; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHOLESTIN; CITRININ; CYNARA SCOLYMUS EXTRACT; DILTIAZEM; FIBRIC ACID DERIVATIVE; GUGGULSTERONE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE DERIVATIVE; LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHYTOSTEROL; POLICOSANOL; PRAVASTATIN; PROPRANOLOL; RESIN; SELENIUM; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; AMMI VISNAGA; ARTICHOKE; BLEEDING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMMIPHORA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRATAEGUS; DIARRHEA; DIET; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG MECHANISM; EPIDURAL HEMATOMA; FLUSHING; FOOD DRUG INTERACTION; GARLIC; GINGER; GOUT; HEADACHE; HERBAL MEDICINE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LIVER TOXICITY; MONASCUS PURPUREUS; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE INFECTION; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; REVIEW; RICE; RISK FACTOR; SIDE EFFECT; TEA;

EID: 0038293050     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal of the American Medical Association 2001; 285(May 16): 2486. Can be found in its entirety on-line at http: //hin.nhlbi.nih.gov/projects/slpprojecdayout4.asp?p=20.
2. These charts are available through the U.S. Department of Health and Human Services, NIH Publication No. 01-3305.
3. Austin MA, Hokanson JE. Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B
4. Assmann G. Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998a;19(Suppl M):M8-M14.
5. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998;81:13B-17B.
6. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002 Jan-Feb;16(1):24-28.
7. Gill JM, Herd SL, Tsetsonis NV, Hardman AE. Are the reductions in triacylglycerol and insulin levels after exercise related? Clin Sci 2002 Feb;102(2):223-31.
8. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15.
9. Knopp RH. Estrogen replacement therapy for reduction of cardiovascular risk in women. Curr Opinion Lipidology, 1991;2:240-7.
10. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of Postmenopausal Hormones/Progestin Interventions trial. Obstet Gynecol 1998;92: 982-88.
11. Ottoson UB, Johansson BG, Von Schoultz B. Subtractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746-50.
12. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989;73:606-12.
13. Jensen J, Riis BJ, Strom V, et al. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987;156:6-71.
14. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA. 1997;277(22):1775-1781.
15. Ali A, Mehra MR. Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. Am J Cardiol 1998;82:1543-1545.
16. Yeromenko Y, Lavie L. Homocysteine and cardiovascular risk in patients with diabetes mellitus. Nutr Metab Cardiovasc Dis 2001;11:108-116.
17. Alexander JK. Obesity and coronary heart disease. Am J Med Sci 2001;321:215-224.
18. Fallest-Strobl PC, Koch DD, Stein JH, et al. Homocysteine: a new risk factor for atherosclerosis. Am Fam Phys. 1997;56(6):1607-1612.
19. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use ofstatins. Am Heart J 2001;141(6):957-63.
20. Key TJA, Thorogood M, Appleby PN, et al. Dietary habits and mortality in 11,000 vegetarians and health conscious people: results of a 17 year follow up. BMJ. 1996;313:775-779.
21. Ness AR, Powles JW. Fruit and vegetables and cardiovascular disease: a review. Int J Epidemiol. 1997;26:1-13.
22. De Oliveira e Silva ER, Seidman CE, Tian JJ, et al. Effects of shrimp consumption on plasma lipoproteins. Am J Clin Nutr. 1996;64:712-717.
23. Vorster HH, Benade AJ, Barnard HC, et al. Egg intake does not change plasma lipoprotein and coagulation profiles Am J Clin Nutr, 1992;55:400-410.
24. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels N Engl J Med. 1999;340:1933-1940.
25. Fuentes
26. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990 Jul;31(7):1149-72.
27. Ginsberg HN, Barr SL, Gilbert A, et al. Reduction of plasma cholesterol levels in normal men on an American Heart Association Step 1 Diet with added monounsaturated fat, N Engl J Med 1990;322(9):574-9.
28. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
29. Teixeira SR, Potter SM S4, Weigel R, etal. et al, Effects of feeding 4 levels of soy protein for 3 and 6 weeks on blood lipids and apolipoproteins in moderately hypercholes-terolemic men. Am J Clin Nutr. 2000;71:1077-1084.
30. Crouse JR III, Morgan T, Terry JG, et al. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med. 1999;159:2070-2076.
31. http://circ.ahajourtials.org/math/ge.gif
32. Nestel P. Isoflavones: their effects on cardiovascular risk and functions. Curr Opin Lipidol 2003;14(1):3-8.
33. Harris WS. Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils. Clin Cardiol 1999:22(6 Suppl):1140-3.
34. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fattyacids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112(4):298-304.
35. Abeywardena MY, Head RJ. Longchain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 2001;52(3):361-71.
36. Panayiotou A, Samartzis D, Nomikos T, et al. Lipid fractions with aggregatory and antiaggregatary activity toward platelets in fresh and fried cod (Gadus morhua): correlation with platelet-activating factor and atherogenesis. J Agric Food Chem 2000;48(12):6372-9.
37. Nieuwenhuys CM, Feijge MA, Offermans RF, Kester AD, Hornstra G, Heemskerk JW. Modulation of rat platelet activation by vessel wall-derived prostaglandin and platelet-derived thromboxane: effects of dietary, fish oil on thromboxane-prostaglandin balance. Atherosclerosis 2001;154(2):355-66.
38. Pakala R, Pakala R, Benedict CR, Thromboxane A2 fails to induce proliferation of smooth muscle cells enriched with eicosapentaenoic acid and docosahexaenoic acid, Prostaglandins Leukot Essent Fatty Acids 1999;60(4):275-81.
39. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids - a review. Nutr Metab Cardiovasc Dis 2000;10(1):28-37.
40. Farmer A, Montori V, Dinneen S, Clar C. Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2001;(3): CD003205
41. Jula A, Marnlemi J, Huupponen R, Virtanen A, Rastas M, Ronnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002;287(5):598-605.
42. Grekas D, Kassimatis E. Makedou A, Bacharaki D, Bamichas G, Tourkantonis A. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia. Nephron 2001 Aug;88(4):329-33.
43. Plat J, Mensink RP, Effects of plant sterols and stanols on lipid metabolism and cardiovascular risk. Nutr Metab Cardiovasc Dis 2001;11(1):31-40.
44. Wong NC. The beneficial effects of plant sterols on serum cholesterol. Can J Cardiol 2001 Jun;17(6):715-21.
45. Vanhanen HT, Blomqvist S, Ehnholm C, et al. Serum cholesterol, cholesterol, precursors, and plant sterols in hypercholesterolemic subjects with different apo E phenotypes during dietary sitostanol ester treatment. J Lipid Res. 1993;34:1535-1544.
46. Law M. Plant sterol and stanol margarines and health. Br Med J. 2000;320:861-864.
47. Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86(1):46-52.
48. Eagles CJ Martin U. Non-pharmacological modification of cardiac risk factors: part 3. Smoking cessation and alcohol consumption, J Clin Pharm Ther. 1998;23:1-9.
49. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999 Dec 11;319(7224):1523-8.
50. Gaziano JM, Hennekens CH, Godfried SL, et al. Type of alcoholic beverage and risk of myocardial infarction. Am J Cardiol. 1999;83:52-57.
51. Rifici VA, Stephan EM, Schneider SH, Khachadurian AK. Red wine inhibits the cell-mediated oxidation of LDL and HDL_J Am Coll Nutr. 1999;18:137-143.
52. Burns J, Crozier A, Lean ME. Alcohol consumption and mortality: is wine different from other alcoholic beverages? Nutr Metab Cardiovasc Dis 2001 Aug;11(4):249-58.
53. Rotondo S, Di Castelnuovo A, de Gaetano G. The relationship between wine consumption and cardiovascular risk: from epidemiological evidence to biological plausibility. Ital Heart J 2001 Jan;2(1):1-8.
54. Wong NC. The beneficial effects of plant sterols on serum cholesterol. Can J Cardiol 2001 Jun;17(6):715-215
55. Criqui MH. Do known cardiovascular risk factors mediate the effect of alcohol on cardiovascular disease? Novartis Found Symp. 1998: 216:159-167; discussion, 167-172.
56. Mosca L, Grundy SM, Judelson D, et al. Guide to preventive cardiology for women: AHA/ACC Scientific Statement: Consensus Panel Statement. Circulation. 1999;99:2480-2484.
57. Stein JH, Keevil JG, Wiebe DA. et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999;100:1050-1055.
58. Carmena R, Ascaso JF, Real JT. Impact of obesity in primary hyperlipidemias. Nutr Metab Cardiovasc Dis 2001 Oct;11(5):354-9.
59. Gordon DJ. Factors affecting high density lipoproteins. Endocrinol Metab Clin North Am. 1998: 27:699-709.
60. Willett W, Hennekens CH, Castelli W, et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am Heart J 1983 Mar;105(3):417-21.
61. Gidding SS. Active and passive tobacco exposure. Prog Pediatr Cardiol. 2001 Jan;12(2):195-198.
62. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000 Dec 21: 86(12A):35L-40L.
63. Willett W, Hennekens CH, Castelli W, et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am Heart J 1983 Mar;105(3):417-21.
64. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins. or the combination for the prevention of coronary disease. N Engl J Med 2001: 29;345(22):1583-92.
65. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002 Feb;143(2):356-65.
66. Carmena R, Ascaso JF, Real JT. Impact of obesity in primary hyperlipidemias. Nutr Metab Cardiovasc Dis 2001 Oct;11(5):354-9.
67. Heber D, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231-236.
68. Stuart MD. Chinese Materia Medica - vegetable kingdom. Taipai, Republic of China: Southern Materials Center, Inc, 1979.
69. McCarthy M. FDA bans red yeast rice product. Lancet 1998;351:1637.
70. Keithley JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 2002 Feb;18(2):201-4.
71. Heber D, et al. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 2001;7(2):133-9.
72. Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia h for the primary prevention of coronary disease: are higher doses oflovostatin cost-effective? Arch Intern Med 1998;158:375-81.
73. Silagy CA, Neil HA. A meta-analysis of the effect of garlic on blood pressure. J Hyperten 1994;12:463-8.
74. Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993;119:599-605.
75. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypereholesterolemia. Ann Intern Med 2000;133:420-9.
76. Gordon DJ. Factors affecting high density lipoproteins. Endocrinol Metab Clin North Am. 1998;27:699-709.
77. Agency for Healthcare Research and Quality, Garlic: Effects on Cardiovascular Risks and Disease, Protective Effects Against Cancer, and Clinical Adverse Effects. Summary, Evidence Report/Technology Assessment: Number 20. Rockville, Md: Agency for Healthcare Research and Quality: October 2000: AHRQ Publication No. 01-E022. Available at: http://www.ahrq.gov/elinie/garlicsum.htm. Accessed August 24, 2001.
78. Lawson LD, Wang ZJ, Papadimitriou D, Allicin release under simulated gastrointestinal conditions from garlic powder tablets employed in clinical trials on serum cholesterol. Planta Med 2001 Feb;67(1):13-8.
79. Lawson LD, Wang, ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J Agric Food Chem 2001 May: 49(5):2592-9.
80. Silagy CA, Neil HA. Garlic as a lipid lowering agent - a meta-analysis. J R Coll Physicians Loud 1994 Jan-Feb;28(1):39-45.
81. Siegel G, Walter A, Schnalke F, et al. Potassium channel activation, hyperpolarization, and vascular relaxation. Z Kardiol 1991;80(suppl 7): 9-24.
82. Siegel G, Emden J, Wenzel K, Mironneau J, Stock G. Potassium channel activation in vascular smooth muscle. Adv Exp Med Biol 1992;311:53-72.
83. Legnani C, Frascaro M, Guazzaloca G, et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 1993;43:119-22.
84. Gadkari JV, Josh VDJ. Effect of ingestion of raw garlic on serum cholesterol level, clotting time and fibripolytic activity in normal subjects. J Postgrad Med 1991;37:128-31.
85. Gebhardt R. Inhibition of cholesterol biosynthesis in primary cultured rat hepatocytes by artichoke (Cynara scolymus L.) extracts. J Pharmacol Exp Ther 1998 Sep;286(3):1122-8
86. Lawson LD. Garlic: A Review of its Medicinal Effects and Indicated Active Compounds. In: Lawson LK, Bauer R (Eds). Phytomedicines of Europe: Chemistry and Biological Activity. Washington DC: American Chemical Society, 1998:176-209.
87. Lawson LD, Ransom DK, Hughes BG. Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial garlic products. Thromb Res 1992;65:141-56.
88. Ali M, Thomson M. Consumption of a garlic clove a day could be beneficial in preventing thrombosis. Prostaglandins Leukot Essent Fatty Acids 1995;53(3):211-2.
89. Ali M, Bordia T, Mustafa T. Effect of raw versus boiled aqueous extract of garlic and onion on platelet aggregation. Prostaglandins Leukot Essent Fatty Acids 1999 Jan;60(1):43-7.
90. Koscielny J, Schmitt R, Radtke H, Latza R, Kiesewetter H. Garlic study vindicated by official investigation. Nature 2000 Apr 6;404(6778):542.
91. Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstruc Surg 1995;95:213.
92. Rose KD, Croissant PD, Parliament CF, Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic consumption: a case report. Neurosurgery 1990;26: 880-82.
93. , Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence, Ann Pharmacother 2000 Dec;34(12):1478-82.
94. Singh K, Chandler R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein, Phytother Res 1997;11:291-4.
95. Urizar NL, Liverman AB, Dodds DT, et al. A Natural Product That Lowers Cholesterol as an Antagonist Ligand for the FXR. Science 2002 May 2; [epub ahead of print]
96. Nityanand S, Kapoor NK. Hypoeholesterolemic effect of Commiphora mukul resin (Guggal). Indian J Exp Biol 1971;9:367-77.
97. Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid - a new hypolipidemic agent. J Assoc Phys India 1989;37:323-38.
98. Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstruc Surg 1995;95:213.
99. Singh RB, Niaz MA, Ghosh S. Hypolipidemie and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercho[es hypercholesterolemia. Cardiovasc Drugs Ther 1994;8(4):659-64.
100. McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal Products Association's Botanical Safety Handbook. Boca Raton: CRC Press, 1997.
101. Dalvi SS, Nayak VK, Pohujani SM, Desai NK, Kshirsagar NA, Gupta KC. Effect of gugulipid on bioavailability of diltiazem and propanolol. J Assoc Phys Ind 1994;42:454-55.
102. Kirchhoff R, Beckers CH, Kirchhoff GM, Trinczek-Gärtner H, Petrowitz O and Reimann H-J (1994) Increase in choleresis by means of artichoke extract. Results of a randomised placebo-controlled double-blind study. Phytomedicine 1:107-115.
103. Heckers H, Dittmar K, Schmahl FW, Huth K. Inefficiency of cynarin as therapeutic regimen in familial type 11 hyperlipoproteinaemia. Atherosclerosis 1977 Feb;26(2):249-53.
104. Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 2000 Mar;50(3):260-265.
105. Cook NC, Samman S. Flavonoids - chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 1996;7:66-76.
106. Manach C, Regerat F, Texier O, et al. Bioavailability, metabolism and physiological impact of4-oxo-flavonoids. Nutr Res 1996;16:517-44.
107. Aviram M., Fuhrman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis 1998a:137: S45-S50.
108. Xia J, Allenbrand B, Sun G. Y. Dietary supplementation of grape polyphenols and chronic ethanol administration on LDL oxidation and platelet function in rats. Life Sci. 1998;63:383-390.
109. Fuhrman B, Buch S, Vaya J, et al. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 1997;66:267-75.
110. Yang M, Wang C, Chen H. Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. J Nutr Biochem 2001;12(1):14-20.
111. Silagy CA, Neff HA. Garlic as a lipid lowering agent - a meta-analysis, J R Coll Physicians Lond 1994 Jan-Feb;28(1):39-45.
112. Bursill C, Roach PD, Bottema CD, Pal S. Green tea upregulates the low-density lipoprotem receptor through the sterol-regulated element binding Protein in HepG2 liver cells. J Agric Food Chem 2001 Nov;49(11):5639-45.
113. Yang TT, Koo MW. Chinese green tea lowers cholesterol level through an increase in fecal lipid excretion. Life Sci 2000;66(5):411-23
114. Brown BG, Zhao XQ Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;29;345(22):1583-92.
115. Peters U, Poole C, Arab L Does Tea Affect Cardiovascular Disease? A Meta-Analysis American Journal of Epidemiology 2001;154 (6):495-503.
116. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001;131(11):2932-5.
117. Kamal-Eldin A, Frank J, Razdan A, Tengblad S, Basu S, Vessby B. Effects of dietary phenolic compounds on tocopherol, cholesterol, and fatty acids in rats. Lipids 2000 Apr;35(4):427-35.
118. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, et al. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis, Atherosclerosis 1999;147(2):371-8.
119. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Bioehem Pharmacol 1999;58(7):1167-72.
120. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 1999, 13(2):245-9.
121. Tanabe M, Chen YD, Saito K, Kano Y. Cholesterol biosynthesis inhibitory component from Zingiber officinale Roscoe. Chem Pharm Bull 1993;41(4):710-3.
122. Srinivasan K, Sambaiah K. The effect of spices on cholesterol 7 alpha-hydroxylase activity and on serum and hepatic cholesterol levels in the rat. Int J Vitam Nutr Res 1991;61(4):364-9.
123. Bhandari U. Sharma JN, Zafar R, The protective action of ethanolic ginger (Zingiber officinale) extract in cholesterol fed rabbits. J Ethnopharmacol 1998;61(2):167-71.
124. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc,) and fenugreek (Trigonel]a foenum graecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997;56(5):379-84.
125. Weidner MS, Sigwart K. The safety of ginger extract in the rat. J Ethnopharmacol 2000 Dec;73(3):513-20.
126. Zhang Z, Ho WK, Huang Y, James AE, Lam LW, Chen ZY. Hawthorn fruit is hypolipidemic in rabbits fed a high cholesterol diet. J Nutr 2002 Jan;132(1):5-10.
127. Rajendran S, Deepalakshmi PD, Parasakthy K, Devaraj H, Devaraj SN. Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet, Atherosclerosis 1996 Jun;123(1-2):235-41.
128. Muller A, Linke W, Klaus W. Crataegus extract blocks potassium currents in guinea pig ventricular cardiac myocytes. Planta Med 1999, 65(4):335-9.
129. Schwinger RH, Pietsch M, Frank K, et al. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000,35(5):700-7.